Global Dengue Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Dengue Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO (World Health Organization) regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree from Ae. albopictus. The diseases transmitted by these vector mosquitoes are chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropics, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever. The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.

Market Overview:

The latest research study on the global Dengue Treatment market finds that the global Dengue Treatment market reached a value of USD 682.86 million in 2022. It’s expected that the market will achieve USD 1701.07 million by 2028, exhibiting a CAGR of 16.43% during the forecast period.

Influence of COVID-19 Outbreak on Dengue Treatment Industry Development

While the world battles to wrestle with the impact of the COVID-19 pandemic, regions with endemic dengue fever are confronting the possibility of a double pandemic that could completely overpower health care services administrations. Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most of the people are confusing it to be dengue at getting themselves tested for dengue too. Simultaneous outbreaks of dengue and COVID-19, as well as probable cases of overlapping infections, have already started in Latin America and certain Asian countries. The challenge of the COVID-19 pandemic threatens to undermine, actions to limit other dengue epidemics.

Overall, co-infection of dengue and COVID-19 is raising complications, and to tackle this unusual scenario which might turn fatal, the governmental bodies are introducing mass vaccination programs, whereas healthcare providers are using balanced tactics to manage both the conditions at once. Precise epidemiological and contact history-taking joined with due attention to false-positive dengue serology and the chance of co-infections are key devices for frontline doctors to overcome this almost insurmountable challenge.

Drivers

In terms of region, the global dengue treatment market has been divided into North America, Europe, Southeast Asia, South Asia, Latin America, and Middle East & Africa. South Asia dominated the global dengue treatment market in 2020.South Asia’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. India and Bengal are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.

Moreover, the recent dengue outbreak in various regions in South Asia indicates that there may be increased risks for future dengue outbreaks in these countries, due to the influx of dengue viruses from overseas combined with the increase in vector population and the expansion of the habitats caused by climate changes, resulting in the rising cases of dengue in South Asia. According to a report published by the Directorate of National Vector Borne Disease Control Program 2019, a total of 67,377 cases of dengue and 48 deaths due to the vector-borne disease have been reported from across India as of October 2019. Thus, considering all the above-mentioned factors, as the number of patients is rising in this region, the testing of the dengue is also expected to rise and boost the growth of the dengue treatment market.

The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue, continuous research, and development of dengue vaccine. In spite of the controlled steps, the global increase in dengue incidence, along with the increased frequency of localized outbreaks and the potential of aedes species to flourish lead to increase in consumption of the treatment option for dengue treatment and is expected to act as a driver for the dengue treatment market.

In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. Rising R&D investment and activities is expected to create lucrative opportunities in the market. Major players in the market are launching their products in emerging markets, instead of opting for developed markets.

Region Overview:

South Asia had the highest growth rate of all regions.

Company Overview:

Pfizer Inc. is one of the major players operating in the Dengue Treatment market, holding a share of 13.76% in 2021.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products.

GlaxoSmithKline plc helps improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. GlaxoSmithKline plc’s Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology.

Segmentation Overview:

Among different product types, Vaccination segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Dengue Treatment market covered in Chapter 3:

Fresenius Kabi USA
Pfizer Inc.
Baxter
Perrigo Company plc
Hikma Pharmaceuticals PLC
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Teva Pharmaceuticals
Dr. Reddy’s Laboratories Limited
Sanofi
Aurobindo Pharma
Mylan N.V
Sun Pharmaceutical Industries Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the Dengue Treatment market from 2018 to 2029 is primarily split into:

Medication
Supportive Care
Vaccination
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Dengue Treatment market from 2018 to 2029 covers:

Hospitals
Specialty Clinics
Home Healthcare
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)